Restless Legs Syndrome Market By Medication Type (Antihistamines , Anti-nausea drugs , Antipsychotic drugs, Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants, Others), By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Restless Legs Syndrome Market size was valued at USD x billion in 2021 and is expected to reach USD x billion by 2028, at a CAGR of x% during the forecast period 2022 to 2028. Restless legs syndrome (RLS), otherwise called Willis-Ekbom infection, is a condition that causes awkward sensations, regularly in the legs. These sensations have been portrayed as tingly, slithering, disturbing sensations, and make the staggering urge move the influenced appendage. RLS side effects commonly happen when the individual is sitting, resting, or dozing, and regularly occur around evening time. The developments caused by RLS are called periodic limb movements of sleep (PLMS). On account of these developments, RLS can cause serious sleep issues. The presently accessible medications in restless legs syndrome can just conveyed to target particular patients for symptomatic alleviation as it were. Also, a portion of the unfriendly impacts, for example, sensory system issue that incorporate migraine, dazedness, sedation, sickness, fart and dry mouth. Mental disarranges, including diminished charisma and wretchedness. Digestion and healthful issue, including expanded hunger and weight pick up; ear issue, maze issue and other normal issue, for example, peevishness, exhaustion, and fringe edema are connected with the utilization of these medications. In this way the treatment methodology for the fretful legs disorder is as yet not extremely famous and not embraced by the medicinal services specialist co-op on a bigger part. The improvement of new medications that have higher productivity and the insignificant reaction would be exceedingly refreshing in the restless legs syndrome market.

Restless Legs Syndrome Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Restless Legs Syndrome Market

The higher predominance of restless legs syndrome is noted in ladies than in men. RLS can influence individuals everything being equal yet is for the most part seen in moderately aged and elderly individuals. The most well-known manifestations of RLS incorporate awkward tingling and torment in the legs that may cause a disturbance in the rest design and at last influence a patient’s personal satisfaction. In spite of its expanding commonness, the exact reason for RLS isn’t yet known. Nevertheless, with broad examinations being led in the field, the RLS market is relied upon to pick up energy sooner rather than later. Starting at now, specialists quality the expanding occurrence of the malady to hereditary elements and insecurities in the dopaminergic adjust.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Restless Legs Syndrome Market Segmentation

Medication Type
  • Antihistamines
  • Anti-nausea drugs
  • Antipsychotic drugs
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Tricyclic Antidepressants
  • Others
By end user
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The restless legs syndrome market is projected to expand at a CAGR of x% during the forecast period  

AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd, Shire Plc, GlaxoSmithKline

North America is the fastest-growing region for the restless legs syndrome market


  • Biogen, Inc (U.S).
  • Pfizer, Inc. (U.s)
  • Johnson & Johnson Services, Inc. (U.S)
  • Eli Lilly & Company (U.S)
  • Merck & Co., Inc. (U.S)
  • AstraZeneca (UK)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Shire Plc. (Ireland)
  • GlaxoSmithKline (UK)